Official ESCRS | European Society of Cataract & Refractive Surgeons


Low-dose supratarsal triamcinolone acetonide for treatment of refractory vernal keratoconjunctivitis

Search Title by author or title

Session Details

Session Title: Cornea: Medical

Session Date/Time: Monday 16/09/2019 | 08:30-10:30

Paper Time: 09:12

Venue: Free Paper Forum: Podium 2

First Author: : P.Desai INDIA

Co Author(s): :    S. Desai                             

Abstract Details


To assess the efficacy and safety of supratarsal injection of 0.3 ml (12.5mg) triamcinolone acetonide in refractory vernal kerato conjunctivitis (VKC).


Study was performed in a tertiary care centre at the Desai eye hospital, Vadodara, India.


A prospective case series of 30 patients (60 eyes) between 5-20 years of age with refractory VKC(not responding to conventional treatment for three weeks) treated with single low dose supra tarsal triamcinolone acetonide with a mean follow-up of 12 months were studied. Single dose injection was given to primary cases and two doses at six month interval for recurrent cases.


A factorial analysis showed dramatic relief of symptoms which were monitored by completing the QUICK (quality of life in children with vernal kerato conjunctivitis) questionnarie as compared to clinical signs and it was observed that the QUICK symptom score was significantly correlated to clinical sign scores : conjuctival hyperemia (p<0.001),secretion (p=0.042) , chemosis (p=0.012) , superficial punctuate keratopathy (p<0.001) and total sign score (p=0.010) . Recurrence was noted in 16.66% of patients. No complications were noted during the follow-up period except for transient redness. There was no IOP rise and all the patients tolerated the treatment well.


Supratarsal injection of low dose triamcinolone acetonide is an affordable, effective and safe modality for treatment of refractory VKC, but a long term follow-up is required to be conclusive.

Financial Disclosure:


Back to previous